Data Insights
By Company Name
No Filter Selected
By Disease Name
No Filter Selected
By Drug Name
No Filter Selected
By Themes
No Filter Selected
Showing 2 results out of 2
Data Insights
Cannabidiol 3 by Avata Biosciences for Epilepsy: Likelihood of Approval
Cannabidiol 3 is under clinical development by Avata Biosciences and currently in Phase I for Epilepsy. According to GlobalData, Phase...
Data Insights
Cannabidiol 3 by Sapient Therapeutics for Epilepsy: Likelihood of Approval
Cannabidiol 3 is under clinical development by Sapient Therapeutics and currently in Phase I for Epilepsy. According to GlobalData, Phase...